Awakening Caspase-2: Revitalizing the Cure for Dementia & Metabolic Diseases
Available July 2025 – IPCure introduces the first commercially available Caspase-2 selective inhibitor and activity-based probe, opening new avenues for targeted research and drug discovery. Both cell-permeant tools are designed for use in vitro, in cellulo, and in vivo, enabling comprehensive investigation of Caspase-2 function across biological systems.
• Available July 2025
• Available July 2025
Our Mission
Developing Drugs that Target Individual Caspases to Fight Dementia and Inflammatory Diseases
About Frontotemporal Dementia & Our Updates
-
![]()
Frontotemporal Disease
Frontotemporal dementia (FTD) encompasses a range of brain disorders that primarily impact the frontal and temporal lobes, which are crucial for regulating personality, behavior, and language.
-
![]()
The primary symptoms of frontotemporal dementia (...)
The primary symptoms of frontotemporal dementia are marked by profound shifts in behavior and personality. These changes typically encompass (...)
-
![]()
Venture Summit West 2025
IPCURE is proud to announce that it has been selected to present at the upcoming Venture Summit West, taking place on April 2nd & 3rd, 2025 at the Computer History Museum in Silicon Valley. Organized by youngStartup Ventures, the summit is the region's premier event for connecting the most promising startups with the venture capital, corporate venture, and angel investor communities.
